Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma.

Caterina CasciniChiara RattiLaura BottiBeatrice ParmaValeria CancilaAdriana SalvaggioCristina MeazzaClaudio TripodoMario P ColomboClaudia Chiodoni

Published in: Journal of experimental & clinical cancer research : CR (2023)

Overall these data indicate that the TLR9 agonist acts as an in situ anti-tumor vaccine, activating an innate immune response sufficient to suppress local tumor growth while inducing a systemic adaptive immunity with selective expansion of CD8 T cell clones, which are needed for the abscopal effect.

Keyphrases

immune response
toll like receptor
dendritic cells
signaling pathway
electronic health record
big data
inflammatory response
machine learning
data analysis
artificial intelligence